ConductScience.org, home

Comparison · NCT00346073-02f59107

Boostrix Group vs Adacel Group: Number of Subjects With Serious Adverse Events (SAEs).

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Boostrix Group vs Adacel Group: Number of Subjects With Serious Adverse Events (SAEs). Trial comparisons, record NCT00346073-02f59107. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00346073-02f59107

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.005910.003110.0112wilson
Risk in group 20.002620.000720.00952wilson
Risk difference, group 1 minus group 20.00329-0.004150.00891newcombe hybrid score
Risk ratio, group 1 over group 22.250.48810.4log
Odds ratio, group 1 over group 22.260.48710.5log
Number needed to treat, for one more participant with the outcome on Boostrix Group than on Adacel Group304from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Boostrix Group
Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
91,522OG000
Group 2Adacel Group
Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
2762OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With Serious Adverse Events (SAEs).
Description
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame
During the active phase of the study (Day 0 - Day 30)
Population
The analysis was performed on the Total Vaccinated Cohort, which included all subjects with at least one vaccine administration documented.

Source ClinicalTrials.gov

Trial

Title
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
NCT number
NCT00346073
Phases
PHASE3
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Boostrix™, ADACEL®
Lead sponsor
GlaxoSmithKline
Results first posted
2018-08-07

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00346073-02f59107